Summary:
- Matterworks, Inc, a company based in Somerville, MA, has secured Series A funding to support its work in generating unstructured molecular data for predictive biology.
- The funding round was led by Lewis & Clark Partners and OMX Ventures, with other investors including Pillar VC, Germin8 Ventures, Intermountain Ventures, and Tarsadia.
- Matterworks plans to use the funds to expand its model as a service business and enhance its machine learning and scientific operations.
Article:
Matterworks, Inc Secures Series A Funding for Predictive Biology
Matterworks, a leading provider of unstructured molecular data for predictive biology, has recently announced the successful closure of its Series A funding round. The Somerville-based company is dedicated to revolutionizing the field of molecular-omic data analysis through innovative technologies and approaches.
The funding, which remains undisclosed, was spearheaded by prominent investors including Lewis & Clark Partners and OMX Ventures. Other key contributors to the round include Pillar VC, Germin8 Ventures, Intermountain Ventures, and Tarsadia, among others. This influx of capital will enable Matterworks to further develop its model as a service (MaaS) business and bolster its capabilities in machine learning and scientific operations.
Under the leadership of CEO Jack Geremia, Matterworks has introduced Large Spectral Models (LSMs) that leverage self-supervised machine intelligence for the direct interpretation of molecular-omic data. The company’s latest innovation, Pyxis, unveiled in 2024, serves as a generative AI tool for comprehensive untargeted molecular annotation, paving the way for new insights and predictions in complex biological scenarios.
With a focus on driving advancements in predictive biology, Matterworks is poised to make significant strides in the field of molecular data analysis. This recent funding injection will undoubtedly fuel the company’s growth and solidify its position as a leader in the industry.
Stay tuned for more updates from Matterworks as they continue to push the boundaries of predictive biology and molecular data analysis.
